Alluvi, formerly LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist shows remarkable impact in early trial data, with substantial slimming observed in part